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http://dx.doi.org/10.1016/j.jaci.2014.06.035cohorts. Two techniques were used to assign the validation
subjects to subgroups: linear discriminant analysis, or the best
identified discriminator (single cytokine) in combination with
subject disease status (asthma or COPD).
Results: Discriminant analysis distinguished severe asthma from
COPD completely using a combination of clinical and biological
variables. Factor and cluster analyses of the sputum cytokine
profiles revealed 3 biological clusters: cluster 1: asthma
predominant, eosinophilic, high TH2 cytokines; cluster 2: asthma
and COPD overlap, neutrophilic; cluster 3: COPD predominant,
mixed eosinophilic and neutrophilic. Validation subjects were
classified into 3 subgroups using discriminant analysis, or disease
status with a binary assessment of sputum IL-1b expression.
Sputum cellular and cytokine profiles of the validation subgroups
were similar to the subgroups from the test study.
Conclusions: Sputum cytokine profiling can determine distinct
and overlapping groups of subjects with asthma and COPD,
supporting both the British and Dutch hypotheses. These findings
may contribute to improved patient classification to enable
stratified medicine. (J Allergy Clin Immunol 2015;135:63-72.)
Key words: Asthma and COPD overlap, cytokines, factor and
cluster analyses
Asthmaandchronic obstructivepulmonarydisease (COPD)cause
considerable morbidity and consume substantial health care re-
sources.1,2 Both conditions are characterized by airflow obstruction,
which is typically variable and reversible in asthma but fixed in
COPD. However, there is overlap; in severe asthma, there can be
persistent airflowobstructionandpartially reversible airflowobstruc-
tion in COPD. Likewise although some reports have suggested that
there aremarked differences in patterns of the underlying inflamma-
tion,3 cellular mechanisms, inflammatory mediators, and response
to therapy4 between asthma and COPD, others have demonstrated
considerable heterogeneity in severe asthma5-7 and COPD8-11 with
overlap between the conditions.12-14 Indeed, there is an ongoing
debate between the ‘‘Dutch hypothesis,’’ which proposes that asthma
andCOPD aremanifestations of the same basic disease process, and
the ‘‘British hypothesis,’’ which suggests that asthma and COPD are
distinct entities generated by different mechanisms.15
The need to refocus efforts to define the similarities and
differences in asthma, particularly in those with severe disease,
and COPD in terms of cytokine profiles16 is underscored by the
emergence of highly specific anti-inflammatory therapies because
response is more likely to be phenotype rather than disease-
specific.17 This is perhaps best exemplified by anti–IL-5
approaches, which have demonstrated clinical responses related
to underlying eosinophilic lung inflammation in asthma18,19 and63
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FIG 1. Discriminant function of demographic, clinical, lung function, and
sputum cytokines characteristics across asthma and COPD. Hollow trian-
gles indicate asthma and hollow circles indicate COPD.
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Subjects
Subjects with severe asthma or moderate-to-severe COPD were recruited
from a single center at the Glenfield Hospital, Leicester, United Kingdom, into
independent test and validation studies. Assignment to asthma or COPD was
made by the subjects’ physician consistent with definitions of asthma and
COPD according to the Global Initiative for Asthma1 or the Global Initiative
for Chronic Obstructive Lung Disease2 guidelines, respectively, for both the
test and validation groups. All subjects were assessed at stable visits at least
8 weeks free from an exacerbation, defined as an increase in symptoms neces-
sitating a course of oral corticosteroids and/or antibiotic therapy. The subjects
with COPD had participated in an exacerbation study,20,21 and some of the
subjects with asthma had participated in an earlier study.22 All subjects pro-
vided written informed consent, and the studies were approved by the local
Leicestershire, Northamptonshire, and Rutland ethics committee.
Measurements
Demographic, clinical, and lung-function data were recorded including pre-
and postbronchodilator FEV1, forced vital capacity, and symptom scores using
the visual analogue scale. Spontaneous or induced sputum was collected for
sputum total and differential cell counts and bacteriology; cell-free sputum su-
pernatant was used for mediator assessment as described previously.20 Sputum
was produced spontaneously in 93%of the subjects. Positive bacterial coloniza-
tionwas defined as colony-formingunits greater than107/mL sputumorpositive
culture.20,21 Subjects with sputum eosinophil and neutrophil differential cell
counts above 3%23,24 and 61%25 were defined as eosinophilic or neutrophilic,
respectively. Further stratification of the subjects into 4 subgroups on the basis
of their sputum cell counts was also done: pure eosinophilic (eosinophil > 3%
and neutrophil < 61%), pure neutrophilic (eosinophil < 3% and neutrophil >
61%), mixed granulocytic (eosinophil > 3% and neutrophil > 61%), and pauci-
granulocytic (eosinophil < 3% and neutrophil < 61%). Inflammatory mediators
were measured in sputum supernatants using the Meso Scale Discovery Plat-
form (MSD; Gaithersburg, Md). The mediators measured were selected to
reflect cytokines, chemokines, and proinflammatory mediators implicated in
airway disease. The performance of the MSD platform in terms of recovery
of spiked exogenous recombinant proteins has been described previously.16
Sputum inflammatory mediators that were below the detectable range were re-
placed with their corresponding lower limit of detection in subjects with both
asthma and COPD. Twenty-one mediators were included in the test study, and
14 mediators were available in the validation study.
Statistical analysis
See this article’s Online Repository at www.jacionline.org for detailed
statistical methods. All statistical analyses were performed using STATA/ICversion 13.0 for Windows (StataCorp, College Station, Tex) and R version
2.15.1 (R Foundation for statistical computing, Vienna, Austria). Parametric
data were presented as mean with SEM, and log transformed data were pre-
sented as geometric mean with 95% CI. The x2 test or the Fisher exact test
was used to compare proportions, and 1-way ANOVA was used to compare
means across multiple groups; nonparametric data were presented as median
with first and third quartiles, and Kruskal-Wallis test was used to compare sub-
groups. Inflammatory mediators that significantly discriminated across
asthma versus COPD and bacterially colonized versus noncolonized were
identified using receiver operating characteristic (ROC) curves. Factor anal-
ysis was performed on sputum inflammatory mediators, and independent fac-
tor scores were derived and used as input variables in the k-means cluster
analysis to identify subjects’ biological subgroups. The optimal number of
clusters was chosen on the basis of a scree plot, by plotting within-cluster
sum of the squares against a series of sequential numbers of clusters. Linear
discriminant analysis was performed and a classification model developed
from the test study for the validation study. In addition, classification and
regression trees analysis was performed sequentially on all inflammatory me-
diators in the test study that had high discriminant function to identify possibly
clinically relevant cutoff points. The inflammatory mediator cutoff points with
the highest sensitivity ratio in discriminating the clusters together with subject
disease status (asthma or COPD) were applied to classify the validation study
into subgroups. A P value of less than .05 was taken as statistically significant.RESULTS
The clinical and sputum characteristics of the asthma (n5 86)
and COPD (n5 75) test groups are presented in Table I. Subjects
with asthma were younger, had a higher body mass index, better
lung function, fewer symptoms, and a lower smoking pack-year
history than did subjects with COPD. The differential neutrophil
and eosinophil counts were not statistically different between the
groups, but the total cell count was higher in those with COPD.
The sputum inflammatory mediator profiles were distinct with
increased TH2 (IL-5, IL-13, and CCL26) and TH1 mediators
(CXCL10 and 11) in severe asthma compared with COPD and
increased IL-6, CCL2, CCL3, and CCL4 in COPD compared
with severe asthma. Inflammatory mediators that best discrimi-
nated asthma and COPD are presented as ROC curves (see Fig
E1 in this article’s Online Repository at www.jacionline.org).
Sputum CCL5 and CXCL11 levels were substantially higher in
subjects with asthma than in subjects with COPD, with area under
the ROC curves (ROC AUCs) of 0.74 (95% CI, 0.67-0.82; P <
.0001) and 0.72 (95% CI, 0.64-0.80; P < .0001), respectively.
Sputum IL-6 and CCL2 levels were significantly higher in sub-
jects with COPD than in subjects with asthma, with ROC AUCs
of 0.86 (95% CI, 0.81-0.92; P < .0001) and 0.69 (0.61-0.77; P <
.0001), respectively. Discriminant analysis using the combined
clinical, physiological, and biological (inflammatory mediator)
variables completely distinguished the asthma and COPD groups
(Fig 1).
The mediators that best discriminated between bacterially
colonized and noncolonized subjects were sputum IL-1b and
TNF-a, with ROC AUCs of 0.76 (95% CI, 0.68-0.85) and 0.75
(95% CI, 0.66-0.84), respectively (see Fig E2 in this article’s
Online Repository at www.jacionline.org). Factor analysis re-
vealed 4 factors with IL-1b, IL-5, IL-6, and CXCL11 as the
highest loading components, respectively, across the 4 factors
(see Table E1 in this article’s Online Repository at www.
jacionline.org). Subsequent cluster analysis identified 3 clusters
(Table II). Individual clinical and biological comparisons of
subjects with asthma and COPD in clusters 1, 2, and 3 are
presented in Table E2 in this article’s Online Repository at
TABLE II. Summary statistics across the 3 identified biological clusters in the test study
Variable
Cluster 1 Cluster 2 Cluster 3 Pairwise comparison, P value
ANOVA,
P value
Asthma (n 5 55);
COPD (n 5 3)
Asthma (n 5 28);
COPD (n 5 19)
Asthma (n 5 2);
COPD (n 5 39) C1 vs C2 C1 vs C3 C2 vs C3
Males, n (%) 32 (55.2) 26 (55.3) 28 (68.3) .99 .19 .21 .35
Current or ex-smokers, n (%) 22 (37.9) 29 (61.7) 40 (97.6) .015 <.0001 <.0001 <.0001
Pack-year history* 6.6 (3.8-11.6) 11.0 (6.1-19.9) 40.3 (33.6-48.3) .13 <.0001 <.0001 <.0001
Age (y) 55 (1.5) 60 (2.1) 67 (1.8) .038 <.0001 .008 <.0001
Duration of disease (y) 23 (17.2-29.6) 9 (5.8-12.8) 6 (4.0-7.9) <.0001 <.0001 .12 <.0001
BMI (kg/m2) 30.2 (1.0) 28.8 (1.0) 25.3 (0.7) .28 <.0001 .005 .001
Exacerbation number of steroids 3 (0.3) 3 (0.3) 4 (0.4) .31 .002 .047 .007
Maintenance prednisolone dose use, n (%) 34 (58.6) 19 (40.4) 6 (14.6) .06 <.0001 .001 <.0001
Daily prednisolone dose (mg)§ 10 (10-15) 7.5 (5-10) 5 (5-7.5) .008 .006 .5 .003
Daily inhaled corticosteroid dose (mg/d)jj 1800 (1000-2000) 1000 (800-2000) 1000 (800-2000) .024 .28 .4 .08
Pre-FEV1 (L) 2.19 (0.1) 1.74 (0.1) 1.3 (0.1) .002 <.0001 .006 <.0001
Pre-FEV1/FVC ratio (%) 69.0 (1.9) 58.5 (2.3) 49.7 (2.4) <.0001 <.0001 .011 <.0001
Pre FEV1 predicted (%) 77.0 (2.7) 59.9 (3.7) 47.0 (3) <.0001 <.0001 .01 <.0001
Post-FEV1 (L) 2.35 (0.1) 1.88 (0.13) 1.37 (0.09) .005 <.0001 .003 <.0001
Post-FEV1 predicted (%) 81.7 (2.7) 63.9 (3.9) 49.1 (3) <.0001 <.0001 .005 <.0001
Sputum eosinophil count (%) 3.9 (2.4-6.4) 0.7 (0.5-0.9) 2.0 (1.25-3.17) <.0001 .039 <.0001 <.0001
Sputum neutrophil count (%) 58.8 (3.1) 77.18 (3) 59.1 (3.1) <.0001 .95 <.0001 <.0001
Sputum macrophage count (%) 16.6 (12.5-21.9) 12.2 (9.2-16.1) 25.7 (21.24-31.07) .1 .026 <.0001 .002
TCC (3 106 cells/g sputum) 1.31 (1.0-1.8) 4.6 (3.3-6.4) 1.8 (1.3-2.6) <.0001 .15 <.0001 <.0001
Blood eosinophil 3 109/L 0.24 (0.18-0.32) 0.25 (0.2-0.32) 0.21 (0.16-0.27) .73 .54 .28 .66
Blood neutrophil 3 109/L 5.74 (0.3) 5.82 (0.3) 5.77 (0.4) .85 .94 .92 .98
CFU >107/mL or positive culture, n (%) 8 (13.8) 26 (55.3) 9 (21.9) <.0001 .29 .001 <.0001
VAS score-cough (mm) 30 (3.0) 48 (4.0) 36 (4.4) .001 .24 .052 .002
VAS score-dyspnea (mm) 31 (3.5) 46 (3.3) 46 (4.5) .003 .006 .93 .0036
IL-1b (pg/mL) 39.5 (30.8-50.8) 379.5 (257.3-559.8) 23.5 (17.2-32.2) <.0001 .025 <.0001 <.0001
IL-4 (pg/mL) 0.36 (0.36-0.59) 0.36 (0.36-0.59.) 0.36 (0.36-0.36) .58 .013 .07 .004
Detectable IL-4, n (%) 20 (34.5) 13 (27.7) 2 (4.9) .45 <.0001 .005 .001
IL-5 (pg/mL) 2.6 (1.6-4.2) 2.2 (1.4-3.4) 1.4 (0.9-2.2) .56 .083 .22 .22
IL-6 (pg/mL) 21.3 (15-30.4) 271.4 (192.2-383.3) 486.2 (327.7-721.4) <.0001 <.0001 .031 <.0001
IL-6R (pg/mL) 163.2 (126.0-211.6) 433.4 (344.2-545.6) 112.4 (88.6-142.6) <.0001 .04 <.0001 <.0001
IL-8 (pg/mL) 1658 (1205-2280) 10884 (8709-13603) 3059 (2209-4236) <.0001 .005 <.0001 <.0001
IL-10 (pg/mL) 0.33 (0.25-0.45) 5.5 (3.5-8.7) 0.34 (0.2-0.6) <.0001 .89 <.0001 <.0001
IL-13 (pg/mL) 10.4 (7.7-14.0) 4.8 (3.8-6.2) 3.5 (2.4-5.2) .001 <.0001 .18 <.0001
IL-17 (pg/mL) 2.12 (2.12-3.97) 2.12 (2.12-5.85) 2.12 (2.12-2.12) .48 .003 .006 .002
Detectable IL-17, n (%) 20 (34.5) 19 (40.4) 0 (0.0) .53 <.0001 <.0001 <.0001
CCL-2 (pg/mL) 209.8 (168.3-261.5) 495.4 (378.1-649.1) 764.5 (538.8-1084.7) <.0001 <.0001 .055 <.0001
CCL-3 (pg/mL) 20.2 (14.9-27.4) 97.4 (71.6-132.6) 47.9 (35.7-64.1) <.0001 <.0001 .002 <.0001
CCL-4 (pg/mL) 237.8 (147.1-384.3) 1138.3 (847.8-1528.3) 807 (614.1-1060.5) <.0001 <.0001 .1 <.0001
CCL-5 (pg/mL) 5.6 (4.5-7.0) 14.9 (11.1-20.1) 2.2 (1.8-2.8) <.0001 <.0001 <.0001 <.0001
CCL-13 (pg/mL) 18.1 (12.9-25.5) 18.9 (13.6-26.2) 43.2 (32.6-57.2) .86 <.0001 <.0001 <.001
CCL-17 (pg/mL) 27 (19.2-37.9) 20.5 (14.0-30.0) 30.8 (21.5-44.2) .28 .61 .13 .31
CCL-26 (pg/mL) 12.4 (7.8-19.9) 5.0 (3.4-7.5) 2.9 (1.9-4.6) .004 <.0001 .081 <.001
CXCL-10 (pg/mL) 418.7 (286.9-611.1) 860.1 (534.1-1384.9) 381.8 (262.5-555.3) .014 .76 .012 .016
CXCL-11 (pg/mL) 34.1 (22.8-51.0) 42.5 (20.1-89.6) 19.2 (12.3-30.0) .56 .15 .089 .15
TNF-a (pg/mL) 1.4 (1.1-1.9) 29.9 (19.5-45.9) 1.7 (1.1-2.5) <.0001 .62 <.0001 <.0001
VEGF (pg/mL) 1020 (858-1213) 2199 (1871-2584) 1237 (1040-1471) <.0001 .12 <.0001 <.0001
IFN-g (pg/mL) 0.13 (0.13-0.13) 0.23 (0.13-1.7) 0.13 (0.13-0.14) <.001 .4 .012 .001
Detectable IFN-g, n (%) 11 (19) 24 (51.1) 11 (26.8) .001 .35 .02 .002
Data presented as geometric mean (95% CI) unless otherwise stated.
BMI, Body mass index; C, cluster; CFU, colony-forming units; FVC, forced vital capacity; TCC, total sputum cell count; VAS, visual analog scale; VEGF, vascular endothelial
growth factor.
*Pack-year history of current and ex-smokers.
Mean (SEM).
Median (first and third quartiles).
§Dose for only those subjects prescribed daily prednisolone.
jjBeclomethasonedipropionate equivalent.
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formed to verify the determined clusters and to identify the
contribution of inflammatory mediators in discriminating the
clusters. Subsequently, 2 discriminant scores for individualsubjects were calculated and used to represent the clusters in
a 2-dimensional graph (Fig 2).
Cluster 1 consisted of mainly subjects with asthma (95% of
cluster 1) with elevated sputumTH2mediators andwas eosinophil
FIG 2. The 3 identified biological clusters presented using subjects’
discriminant scores. Hollow triangles indicate eosinophilic asthma domi-
nant (95% asthma, n 5 58); bold triangle and bold circle, neutrophilic
asthma and COPD (overlap) dominant (59.6% asthma, n 5 47); hollow cir-
cle, COPD dominant (95% COPD, n5 41); bold triangle, overlapped asthma;
bold circle, overlapped COPD.
FIG 3. Absolute IL-1b concentrations on a log scale (base 10) across the 3
identified biological clusters. A, Asthma; C, COPD. P is the P value for mean
comparison between cluster 1 or cluster 3 versus cluster 2 (overlap).
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philia and 48% a sputum neutrophilia. Further stratification of
cluster 1 by sputum cell counts showed that the subjects were
40% pure eosinophilic, 21% pure neutrophilic, 27% mixed gran-
ulocytic, and 12% paucigranulocytic.
Cluster 2 consisted of an overlap of subjects with asthma and
COPD with sputum neutrophil predominance (75% of subjects
with asthma and 95% of subjects with COPD). In contrast, only
11% and 5% of the subjects with asthma or COPD, respectively,
had a sputum eosinophilia. In addition, there were elevated
sputum levels of IL-1b, IL-8, IL-10 and TNF-a and bacterial
colonization. The increased rate of bacterial colonization found in
this cluster was driven predominately by subjects with COPD
(Table E2). Further stratification of cluster 2 showed that the sub-
jects were 0% pure eosinophilic, 74% pure neutrophilic, 9%
mixed granulocytic, and 17% paucigranulocytic.
Cluster 3 consisted predominantly of subjects with COPD
(95% of cluster 3). In contrast to subjects with COPD in cluster 2,
neutrophilic inflammationwas present in only 49%of the subjects
whereas a sputum eosinophilia was observed in 46% of the
subjects. IL-6 and CCL2 levels were increased compared with
those in clusters 1 and 2 but were similar to those in subjects with
COPD in cluster 2. Only CCL13 and CCL17 were elevated in
subjects with COPD in cluster 3 compared with subjects with
COPD in cluster 2 (Table E2). Further stratification of cluster 3
showed that the subjects were 21% pure eosinophilic, 28% pure
neutrophilic, 23% mixed granulocytic, and 28% paucigranulo-
cytic. The proportion of subjects with asthma with airflow
obstruction in the 3 clusters was not significantly different. Of
the 2 subjects with asthma in cluster 3, 1 had persistent airflow
obstruction compared with 17 of 55 in cluster 1 and 10 of 28 in
cluster 2.
The best discriminator between subjects in clusters 1 or 3
compared with the overlap group cluster 2 was sputum IL-1b at a
cutoff point of 130 pg/mL (Fig 3). The second best discriminator
was TNF-a with a cutoff point of 5 pg/mL (see Fig E3 in this ar-
ticle’s Online Repository at www.jacionline.org).Validation
These cluster analysis findings were then validated in inde-
pendent asthma and COPD cohorts. Subjects were assigned into
subgroups using 2 techniques. The first was a classification model
developed from the test cohort using linear discriminant analysis
and betas for each cluster and cytokines were extracted (see Table
E3 in this article’s Online Repository at www.jacionline.org). In-
dividual subject discriminant score in each subgroup was calcu-
lated and the subject was assigned to the subgroup in which he
or she had the highest score. The second technique used the IL-
1b cutoff point at 130 pg/mL, which was identified as the best
classifier to distinguish overlap cluster 2 from clusters 1 or 3 in
the test study and was used alongside subject disease status
(asthma or COPD). The sputum cellular and inflammatory medi-
ator profiles of the 3 validation study subgroups, obtained using
both techniques, were very similar to the test subgroups (Tables
III and IV; Fig 4). In addition, individual clinical and biological
comparisons of subjects with asthma and COPD invalidation sub-
groups, presented in this article’s Online Repository in Tables E4
and E5 at www.jacionline.org, revealed a patter similar to that of
test subgroups (Table E2).DISCUSSION
Here we report that although a combination of clinical
variables distinguished asthma from COPD, further analyses of
the sputum inflammatory mediators revealed that patients with
asthma and COPD were best described by 3 biological clusters
incorporating clinical, physiological, and inflammatory mediator
characteristics. Our findings have further underscored the com-
plex heterogeneity of asthma and COPD and provided support for
the ‘‘British’’ hypothesis of airway disease pathogenesis as we
identified 2 clusters that were predominately either asthma or
COPD with distinct cytokine profiles, while also supporting the
‘‘Dutch’’ hypothesis by identifying a third cluster of overlapping
subjects from both disease groups with similar cytokine profiles.
Cluster 1 was asthma predominant with evidence of eosinophilic
inflammation and increased TH2 inflammatory mediators. Clus-
ter 2 contained an asthma and COPD overlap group, with
TABLE III. Summary statistics across the validation subgroups that were identified using linear discriminant analysis
Variable
Group 1 Group 2 Group 3 Pairwise comparison, P value
ANOVA,
P value
Asthma (n 5 94);
COPD (n 5 12)
Asthma (n 5 55);
COPD (n 5 18)
Asthma (n 5 7);
COPD (n 5 28) G1 vs G2 G1 vs G3 G2 vs G3
Males, n (%) 65 (61.3) 40 (54.8) 25 (71.4) .38 .28 .1 .25
Current or ex-smokers 37 (34.9) 42 (57.5) 33 (94.3) .003 <.0001 <.0001 <.0001
Pack-year history* 13.2 (8.5-20.7) 16.0 (10.0-25.6) 39.6 (31.3-50.1) .52 <.0001 .002 <.001
Age (y) 53 (1.3) 56 (2.0) 66 (2.0) .15 <.0001 .002 <.0001
Duration of disease (y) 15 (12.9-18.7) 13 (9.8-16.8) 6 (4.2-8.5) .24 <.0001 .002 <.001
BMI (kg/m2) 30.2 (0.7) 29.0 (0.8) 27.1 (0.9) .22 .017 .13 .05
Exacerbation number of steroids 3 (0.3) 3 (0.3) 3 (0.5) .94 .82 .87 .97
Maintenance prednisolone dose use, n (%) 54 (50.9) 30 (41.1) 7 (20.0) .19 .001 .03 .006
Daily prednisolone dose (mg)§ 10 (10-15) 10 (5-15) 5 (5-10) .52 .03 .12 .11
Daily inhaled corticosteroid dose (mg/d)jj 2000 (1000-2000) 1600 (1000-2000) 1000 (200-2000) .2 <.001 .008 <.001
Pre-FEV1/FVC ratio (%) 68.2 (1.4) 61.8 (1.9) 57.3 (1.8) .004 <.0001 .14 <.001
Pre-FEV1 predicted (%) 67.6 (2.2) 64.7 (2.9) 65.5 (3.2) .4 .65 .85 .69
Sputum neutrophil count (%) 59.1 (2.8) 72.3 (2.5) 58.4 (4.0) .001 .88 .003 .001
Sputum eosinophil count (%) 6.3 (4.9-8.2) 3.0 (2.4-3.8) 3.2 (2.3-4.4) <.0001 .003 .79 <.001
TCC (3 106 cells/g sputum) 1.2 (0.9-1.5) 3.5 (2.5-4.8) 2.99 (2.07-4.3) <.0001 .001 .6 <.0001
IL-1B (pg/mL) 54.1 (42.7-68.5) 526.6 (375.5-738.4) 42.4 (26-69.2) <.0001 .36 <.0001 <.0001
IL-5 (pg/mL) 1.4 (1.1-1.8) 1.2 (0.8-1.7) 0.9 (0.5-1.5) .43 .085 .34 .22
IL-6 (pg/mL) 26.1 (19.9-34.3) 273.3 (210.6-354.6) 344.2 (237.2-499.3) <.0001 <.0001 .32 <.0001
IL-6R (pg/mL) 186.0 (135.5-255.3) 589.8 (476.6-729.8) 90.5 (50.3-162.8) <.0001 .013 <.0001 <.0001
IL-8 (pg/mL) 1210 (822-1783) 10,771 (8,846-13,115) 1387 (643-2989) <.0001 .7 <.0001 <.0001
IL-10 (pg/mL) 1.9 (1.5-2.4) 3.9 (2.8-5.4) 0.5 (0.3-0.9) .001 <.0001 <.0001 <.0001
CCL-2 (pg/mL) 191.9 (161.7-227.8) 425.6 (338.6-535.0) 680.1 (486.9-949.8) <.0001 <.0001 .025 <.0001
CCL-4 (pg/mL) 119.6 (80.3-178.1) 848.1 (646.8-1111.9) 502.5 (248-1018.2) <.0001 <.0001 .1 <.0001
CCL-5 (pg/mL) 4.5 (3.7-5.6) 16.8 (13.3-21.2) 3.8 (2.6-5.5) <.0001 .39 <.0001 <.0001
CCL-13 (pg/mL) 17.4 (14.5-21.0) 18.4 (14.2-23.9) 40.0 (27.7-57.9) .73 <.0001 .001 <.001
CCL-17 (pg/mL) 21.3 (16.4-27.7) 25.2 (19.0 -33.4) 36.0 (23.3-55.6) .4 .043 .17 .12
CXCL-10 (pg/mL) 235.8 (167.7-331.7) 841.5 (566.5-1249.9) 254.1 (140.7-458.8) <.0001 .83 .001 <.0001
CXCL-11 (pg/mL) 12.4 (8.7-17.6) 36.1 (22.1-59.1) 23.6 (15.4-35.9) <.0001 .08 .28 <.001
TNF-a (pg/mL) 1.4 (1.2-1.7) 23.3 (16.1-33.7) 1.8 (1.1-3.0) <.0001 .32 <.0001 <.0001
Groups 1, 2 and 3 were predicted using linear discriminant analysis. Data presented as geometric mean (95% CI) unless otherwise stated.
BMI, Body mass index; FVC, forced vital capacity; G, group.
*Pack-year history of current and ex-smokers.
Mean (SEM).
Median (first and third quartiles).
§Dose for only those subjects prescribed daily prednisolone.
jjBeclomethasonedipropionate equivalent.
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levels of IL-1b and TNF-a in addition to being assigned the high-
est proportion of subjects with bacterial colonization. Cluster 3
was a COPD-predominant group with mixed granulocytic airway
inflammation and high sputum IL-6 and CCL13 levels. Further-
more, the biological clusters derived from the test group could
be validated in an independent group yielding similar inflamma-
tory mediator profiles to the test group. Whether these biological
clusters can be used to stratify subjects for more targeted ap-
proaches to novel and existing therapies needs to be further
studied.
The clusters we have identified have biological plausibility and
they confirm and extend our current understanding of the
immunopathobiology of asthma and COPD, moving our under-
standing beyond previous comparisons of asthma versus COPD16
or clustering approaches of cytokine profiles in asthma or COPD
alone.20,26 In addition, the clusters might represent groups with
possible stratified responses to specific anti-inflammatory treat-
ment. Cluster 1 is consistent with the TH2-predominant eosino-
philic asthma paradigm. Indeed, this group was predominately
asthmatic but importantly also included about 5% of subjectswith COPD. It would seem likely that this group is most likely
to respond to anti-TH2 cytokine therapy such as anti–IL-5 and
13.18,19,27,28 Eosinophilic COPD is well-described, and this group
has a greater response to oral and inhaled corticosteroids than did
those with noneosinophilic COPD.29,30 Whether subjects with
COPD in this cluster would respond to anti-TH2 cytokine therapy
is currently under study (www.clinicaltrials.gov NCT01227278).
Cluster 2 included an overlap of subjects with asthma and COPD.
This group was predominately neutrophilic, consistent with pre-
vious observations,14 and with increased bacterial colonization.
Recent evidence supports the role for macrolide antibiotics in
COPD31 and in noneosinophilic severe asthma.32 Antineutro-
philic strategies such as anti-CXCR2 are currently under study.33
Further studies are required to assess whether this cluster repre-
sents patients most likely to respond to these therapies. In cluster
2, increased bacterial colonization was evident, particularly in
those with COPD, perhaps suggesting that in these subjects the
neutrophilic inflammation is a consequence of bacterial coloniza-
tion rather than the primary abnormality. Thus, whether amelio-
rating neutrophilic inflammation in this group is beneficial or
harmful is unclear. Indeed, lessons from anti–TNF-a therapy
TABLE IV. Summary statistics across the validation subgroups that were identified using IL-1b cutoff and subject disease status
(asthma or COPD)
Variable
Group 1 Group 2 Group 3 Pairwise comparison, P value
ANOVA,
P valueAsthma (n 5 103)
Asthma (n 5 63);
COPD (n 5 26) COPD (n 5 32) G1 vs G2 G1 vs G3 G2 vs G3
Males, n (%) 66 (64.1) 51 (57.3) 22 (68.7) .34 .63 .26 .44
Current or ex-smokers 28 (27.2) 54 (60.7) 32 (100) <.0001 <.0001 <.0001 <.0001
Pack-year history* 9.5 (5.8-15.7) 17.0 (11.5 -25.2) 41.5 (33.5-51.6) .06 <.0001 .001 <.001
Age (y) 49 (1.2) 57 (1.8) 68 (1.6) <.0001 <.0001 .001 <.0001
Duration of disease (y) 17 (14.1-20.7) 13 (10.6-16.6) 4 (2.7-4.7) .08 <.0001 <.0001 <.0001
BMI (kg/m2) 29.9 (0.7) 29.0 (0.6) 27 (1.3) .33 .03 .13 .09
Exacerbation number of steroids 3 (0.3) 3 (0.3) 2 (0.4) .41 .05 .13 .14
Maintenance prednisolone dose use, n (%) 57 (55.3) 35 (39.3) 2 (6.25) .027 <.0001 <.0001 <.0001
Daily prednisolone dose (mg)§ 10 (8-15) 10 (5-10) 6.25 (5-7.5) .15 .11 .24 .12
Daily inhaled corticosteroid dose (mg/d)jj 1600 (1000-2000) 2000 (1000-2000) 900 (200-2000) .52 .006 .008 .13
Pre-FEV1/FVC ratio (%) 70.1 (1.2) 61.0 (1.7) 56.6 (2.4) <.0001 <.0001 .16 <.0001
Pre-FEV1 predicted (%) 71.2 (2.3) 64.1 (2.5) 60.2 (3.6) .033 .019 .4 .022
Sputum neutrophil count (%) 59.0 (2.8) 70.4 (2.5) 59.2 (4.2) .003 .97 .023 .006
Sputum eosinophil count (%) 5.6 (4.3-7.3) 3.5 (2.8-4.4) 3.9 (2.5-5.9) .009 .12 .68 .028
TCC (3 106 cells/g sputum) 0.98 (0.7-1.3) 3.1 (2.3-4.1) 3.1 (2.2-4.5) <.0001 <.0001 .97 <.0001
IL-1B (pg/mL) 37.0 (29.1-47) 527.1 (407.1-682.5) 40.0 (28.2-56.6) <.0001 .75 <.0001 <.0001
IL-5 (pg/mL) 1.2 (1.0 -1.5) 1.3 (1.0 -1.9) 1.0 (0.6-1.7) .69 .45 .37 .59
IL-6 (pg/mL) 34.7 (25.6-47) 190 (138.4-261) 157.7 (88.8-280.2) <.0001 <.0001 .56 <.0001
IL-6R (pg/mL) 153 (102.7-228.6) 549.4 (454.9-663.6) 101.7 (74.1-139.5) <.0001 .17 <.0001 <.0001
IL-8 (pg/mL) 975 (597-1592) 8,609 (7,062- 10,496) 1646 (1041-2603) <.0001 .15 <.0001 <.0001
IL-10 (pg/mL) 2.2 (1.8-2.6) 3.1 (2.2-4.3) 0.4 (0.2-0.6) .063 <.0001 <.0001 <.0001
CCL-2 (pg/mL) 202 (166.8-244.9) 414.8 (336.4-511.6) 488.3 (340.0-701.4) <.0001 <.0001 .44 <.0001
CCL-4 (pg/mL) 101.3 (65.3-157.3) 685.4 (497.8-943.8) 631.5 (382.8-1041.7) <.0001 <.0001 .79 <.0001
CCL-5 (pg/mL) 5.2 (4.1-6.7) 11.7 (9.2-14.8) 3.7 (2.5-5.5) <.0001 .16 <.0001 <.0001
CCL-13 (pg/mL) 14.7 (12.4-17.5) 22.0 (17.1-28.3) 39.4 (27.4-56.6) .01 <.0001 .017 <.0001
CCL-17 (pg/mL) 19.5 (15.1-25) 26.1 (19.7-34.7) 35.7 (22.9-55.6) .13 .025 .26 .057
CXCL-10 (pg/mL) 250.5 (163-384) 595.4 (420.6-842.9) 297.7 (194.2-456.6) .002 .64 .034 .0052
CXCL-11 (pg/mL) 17.3 (12.4-24.2) 25.0 (16.3-38.5) 15.8 (7.8-31.8) .18 .81 .28 .32
TNF-a (pg/mL) 1.6 (1.3-2.0) 14.4 (9.8-21.2) 1.3 (0.7-2.1) <.0001 .39 <.0001 <.0001
Data presented as geometric mean (95% CI) unless otherwise stated.
BMI, Body mass index; G, group; group 1, pure asthma (IL-1B < 130 pg/mL); group 2, asthma and COPD overlap (IL-1B >_ 130 pg/mL); group 3, pure COPD (IL-1B < 130 pg/mL);
FVC, forced vital capacity; TCC, total sputum cell count.
*Pack-year history of current and ex-smokers.
Mean (SEM).
Median (first and third quartiles).
§Dose for only those subjects prescribed daily prednisolone.
jjBeclomethasonedipropionate equivalent.
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the risk of infection.34,35 In contrast, in those with neutrophilic
inflammation without evidence of bacterial colonization, particu-
larly in thosewith asthma, the neutrophilic inflammationmight be
critical in the development of the disease. Thus, identification of
distinct groups that benefit or are harmed by antineutrophilic ap-
proaches would enable better stratification of such therapies.
Cluster 3 included mainly subjects with COPD in which bacterial
colonization was observed in fewer subjects in spite of consis-
tently elevated proinflammatory cytokines. Perhaps this group,
in contrast to cluster 2, represents subjects in which the proinflam-
matory environment plays a more causal role in the disease
expression rather than as a consequence of infection. This might
suggest that this group would be more amenable to anticytokine
therapies such as anti–IL-6. In addition, eosinophilic inflamma-
tion was a feature in some subjects in cluster 3 in the absence
of an elevated TH2 profile. One of the few cytokines increased
in cluster 3 was CCL13, which is a CCR3 agonist and promotes
eosinophil migration. Small airway macrophages are an impor-
tant source of CCL13 in the airway and might play a role in theeosinophilic inflammation in this group.36 Taken together, these
intriguing and novel observations immediately open up opportu-
nities for further translational studies to determine the underlying
mechanisms of these clusters and their treatment-specific anti-
inflammatory therapies.
In addition to clear differences in the cytokine profiles between
groups, there were several differences in clinical parameters.
These were largely dependent on whether the clusters were
asthma or COPD predominant or mixed. For example, lung
function, age, greater smoking history, and higher exacerbation
frequency was related to the number of subjects with COPD in the
cluster. However, the symptom of cough was more common in
cluster 2. Indeed, subjects with asthma and COPD in cluster 2 had
a higher visual analog scale score for cough than did either the
subjects with asthma in cluster 1 or the subjects with COPD in
cluster 3, respectively. This suggests that this difference is
independent of disease status and might represent a real associ-
ation either between the inflammatory profile or increased
bacterial colonization in cluster 2. This cluster also had the
highest sputum total inflammatory cell count, suggesting that
FIG 4. Cytokine profiles in the test and the validation groups using linear discriminant analysis or IL-1b
cutoff and disease for cluster 1 (A), cluster 2 (B), and cluster 3 (C). Circles indicate test study, triangles
indicate validation using linear discriminant analysis, and rectangles indicate validation using IL-1b cutoff
at 130 pg/mL and disease status (asthma or COPD). The y-axes depict the mean z value (standardized) of
each cytokine in each test and validation subgroup.
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above, whether this group might warrant antimicrobial,
anti-inflammatory, or antimucolytic therapy is an interesting
possibility.
One of the strengths of our observations is that we were able to
support the identification of the 3 biological clusters in an
independent validation group. The similarity between the cyto-
kine (inflammatory mediators) profiles in test and validation
groups supports the view that each cluster is a consistent
phenotype and might reflect common immunopathology and
phenotype-specific responses to treatment. We found biological
clusters that were asthma or COPD predominant, suggesting that
there are distinct mechanisms underlying these groups, but we
also identified a consistent overlap group that might be aconsequence of shared mechanisms. Two approaches were used
to validate the clusters in an independent group using discrimi-
nant analysis and the generation of a classifier that used the
disease allocation and sputum IL1b cutoff. Sputum IL-1bwas the
best discriminator between the subjects with asthma or COPD in
clusters 1 and 3, respectively, with those in the overlap group
cluster 2. The clinical diagnosis of asthma or COPD together with
a single sputum cytokine (IL-1b cutoff) demonstrated a simple
approach to segment asthma and COPD populations into 3 groups
with distinct and consistent cytokine profiles. This approach has
advantages in its simplicity and offers the potential for immediate
use in stratified medicine studies although it might underestimate
small, albeit potentially important subgroups such as TH2 high
COPD.
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severe asthma and COPD who attended a secondary care setting
were included, and thus might not be representative of a more
generalized population. We concede that our findings cannot be
extrapolated to mild to moderate asthma or mild COPD but are
confident that our test and validation populations are representa-
tive of our broader secondary care patient population. Our earlier
preliminary data comparing asthma and COPD included subjects
across the severity of disease and in this analysis fewer
differences between asthma and COPD were observed.16
Whether this was due to lack of power because of the small
numbers or due to masking clearer differences in more severe dis-
ease is unknown. Further studies are required to include healthy
controls, larger disease populations including a broader spectrum
of subjects including those with mild disease, and comparisons
with other disease control groups. Allergic sensitization might
also be an important mechanism in driving the different clusters.
We did not record atopic status in the COPD group consistently,
but in those with asthma there was no difference across the clus-
ters. However, future studies should consider the role of allergy in
these clusters. Our study has focused on stable visits and a similar
comparison is required for longitudinal follow-up at stable and
exacerbation events. We have previously reported exacerbation
biological clusters in subjects with COPD and interestingly
have identified similar profiles as described here.20Whether com-
parisons of cytokine profiles in larger groups of subjects with se-
vere asthma and COPD reveal similar biological clusters needs to
be addressed. The cytokine profiles have been derived from
sputum analysis and whether the profiles are similar in tissue sam-
ples is unknown. Access to bronchoscopic samples from large
numbers of subjects with COPD and asthma with severe disease
is challenging, but multicenter efforts to address this are under-
way in parallel with sputum sampling and these findings are
eagerly awaited. In addition, although we have chosen to measure
a large number of mediators implicated in obstructive airway dis-
ease, these mediators cannot fully reflect the complexity of
airway disease and approaches usingmore comprehensive assess-
ment of inflammatory networks in the airway perhaps using ’omic
approaches such as transcriptomics will be informative.37 Such
studies in small numbers suggest similar groupings described
here with transcriptional profiles associated with cellular profiles
and further studies are awaited.
In conclusion, we found here that sputum inflammatory
mediator profiling can determine distinct and overlapping groups
of subjects with asthma and COPD. We identified an asthma-
predominant cluster with eosinophilic inflammation and elevated
TH2 inflammatory mediators, a COPD-predominant group with
elevated proinflammatory cytokines, and an asthma and COPD
overlap group that clinically had chronic bronchitis, increased
bacterial colonization, elevated sputum IL-1b and TNF-a levels,
and a sputum neutrophilia. We predict that these groups might
contribute to improved patient classification to enable a stratified
medicine approach to airways disease.
Clinical implications: Sputum cytokine profiling can determine
distinct and overlapping asthma andCOPD subgroups support-
ing both the British and Dutch hypotheses of airway disease.
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Statistical analyses were undertaken by Ghebre and verified independently
by Newby. Unsupervised multivariate modeling using factor analysis,
principal factor, with orthogonal varimax rotation, was performed to obtain
a set of low-dimensional independent and interpretable factors. Sampling
adequacy for factor analysis was assessed using Kaiser-Meyer-Olkin.E1 Fac-
tors were retained on the basis of screeplot (factors above the break in the
curve) and eigenvalue above 1. Inflammatory mediators that have high colli-
nearityE2 were excluded from factor analysis to avoid multicollinearity; in
addition, cytokines that have less than 50% communality,E3 total variance ex-
plained by the factors, were excluded from the analysis. Because CXCL10 and
11were highly correlated, and CXCL11’s variancewas better explained by the
factors explored than was CXCL10’s variance, CXCL10 was excluded from
the model. More than 50% of the subjects had undetectable concentrations
of IL-4, IL-17, and IFN-g. Their distributionswere positively skewed and their
total variance was not explained by the factors by more than 50%; therefore,
they were not included in the factor and cluster analyses. Likewise, because
IL-10 levels in more than one-third of asthmatic patients were below the limit
of detection, but the concentrations were not different between asthma and
COPD then, to avoid bias toward one disease, it was excluded from the model.
No similar bias was observed for other inflammatory mediators. Fifteen sub-
jects (1 with asthma and 14 with COPD) who did not have complete record of
the cytokine panel were excluded from the biological factor and cluster anal-
ysis. Factor scores were calculated for each subject using standardized values
and inverse of correlation matrix of the original variables (inflammatory me-
diators), and factor loadings (Table E1). These scores represent the subjects’
predicted value for each factor and retain the relationship between factors,
and were used for constructing clusters.E4 Although it was possible to identify
the underlying structure of the inflammatorymediators using factor analysis, it
was impossible to classify subjects into subgroups who have the same under-
lying structure using factor analysis. Therefore, ‘‘k-means cluster analysis on
factor scores’’ approach was used to identify subjects’ subgroups that have
similar biological profiles. Squared Euclidian distance was used as a measure
of similarity. The use of these 2 approaches (cluster and factor analyses) pro-
vides a dimensional view of both cytokines and subgroups and was used to
explore the unobserved subjects heterogeneity: the factor analysis to capture
the profiles of the cytokines and k-means cluster analysis to allow for the clas-
sification of individuals into subgroups. The optimal number of clusters was
chosen on the basis of screeplot (clusters above the break in the curve) by
plotting within cluster sum of the squares against a series of sequential number
of clustersE5 and by assessing how natural the clusters look on their clinical
and biological implications (phenotypes) and clinical meanings and
interpretability.
Linear discriminant analysis was performed on the cytokines across the
clusters to validate how the identified clusters from the factor scores can be
predicted using cytokines measurements, and to identify the contribution of
each cytokine in discriminating the clusters. Then, discriminant scores (1 lessthan the number of clusters) for each subject were calculated using the
discriminant functions of a cytokine and the original cytokine values for each
subject, and used to represent the subjects’ biological cluster membership
graphically.
Independent patients with severe asthma and COPD were used for
validation. Because the number of cytokines in the validation studies is
smaller than the number of cytokines used to identify subgroups in the test
study, clusters in the test study were predicted using only those cytokines that
existed in the validation group. The betas for each cytokine in each cluster are
depicted in Table E3. The classification model for each cluster was developed
from the betas for each cytokine in the test study and was subsequently applied
in the validation study to assign subjects to subgroups on the basis of the high-
est discriminant score.
The model fit was as follows:
Dij5bj1bj1X1i1bj2X2i1/1bjkXki1log

Pj

where Dij is the discriminant score for subject i in group j, bj is a constant for
the jth group, bjk is the weight (coefficient) for the variable (cytokine) K in
group j, Xki is the observed value of subject i on the kth variable; and
log (Pj) is logarithm of prior probability of group j membership.
In addition, classification and regression trees analysis using the rpart R
packageE6 was performed sequentially to all cytokines in the test study, which
had high discriminant function, to identify clinically relevant cutoff points.
Subsequently, the best determined cytokine cutoff (with the highest sensitivity
ratio in discriminating the clusters), together with the disease classification
(asthma or COPD), was applied to classify the validation study into subgroups.
Parametric data were expressed as mean with SEM, and log transformed
data were presented as geometric mean with 95% CI. The x2 test or the Fisher
exact test was used to compare proportions, and 1-way ANOVAwas used to
compare multiple groups; nonparametric data were presented as median
with first and third quartiles and Kruskal-Wallis test was used to compare sub-
groups. A P value of less than .05 was taken as statistically significant. All sta-
tistical analyses were performed using STATA/IC version 13.0 for Windows
(StataCorp) and R version 2.15.1 (R Foundation for Statistical Computing).
FIG E1. Sputum cytokines, which discriminated across asthma and COPD. ROC AUCwith 95% CI illustrating
biomarkers that predict asthma (A) or COPD (B).
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FIG E2. Cytokines across bacterial colonization and low-bacterial coloniza-
tion. ROC AUC with 95% CI illustrating biomarkers that predict bacterial
colonization.
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FIG E3. Absolute TNF-a concentrations on a log scale (base 10) across the 3
identified biological clusters. A, Asthma; C, COPD. P is the P value for mean
comparison between cluster 1 or cluster 3 versus cluster 2 (overlap).
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TABLE E1. Factor loading matrix for sputum cytokines after
orthogonal varimax rotation
Variable
Factor loadings
C1 U2Factor 1 Factor 2 Factor 3 Factor 4
IL-1b 0.93 088 0.12
IL-5 0.84 0.78 0.22
IL-6 0.81 0.75 0.25
IL-6R 0.73 0.65 0.35
IL-8 0.73 0.50 0.82 0.18
IL-13 0.73 0.56 0.44
CCL-2 0.70 0.55 0.45
CCL-3 0.49 0.56 0.69 0.31
CCL-4 0.59 0.66 0.34
CCL-5 0.65 0.54 0.79 0.21
CCL-13 0.64 0.65 0.35
CCL-17 0.74 0.72 0.28
CCL-26 0.75 0.63 0.37
CXCL-11 0.74 0.64 0.36
TNF-a 0.88 0.82 0.18
VEGF 0.57 0.54 0.46
Eigenvalue 4.05 3.05 2.92 1.12
Pr (%) 35.4 26.7 25.5 9.8
Factor loading less than 0.45 were replaced with blank, but included when estimating
the factor scores. Highest loading variables for each factor are in boldface.
C1, Proportion of total variation accounted for by the common factors (common
variance); Pr, percent of total variation accounted for by each factor; U2, proportion of
total variation not accounted by the common factors (unique variance); VEGF,
vascular endothelial growth factor.
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TABLE E2. Summary statistics by disease and biological subgroups in the test study
Variable
Cluster 1 Cluster 2 Cluster 3
Pairwise comparison,
P value
G1 (asthma in
cluster 1) (n 5 55)
G2 (asthma in
cluster 2) (n 5 28)
G3 (COPD in
cluster 2) (n 5 19)
G4 (COPD in
cluster 3) (n 5 39)
G1 vs
G2
G2 vs
G3
G3 vs
G4
Males, n (%) 29 (52.7) 13 (46.4) 13 (68.4) 27 (69.2) .59 .14 .95
Current or ex-smokers, n (%) 19 (34.5) 11 (39.3) 18 (94.7) 38 (97.4) .67 .023 .6
Pack-year history* 5.5 (3.1-9.8) 2.8 (1.3-5.8) 36.6 (27.8-48.1) 42.1 (35.3-50.2) .16 <.0001 .4
Age (y) 54 (1.6) 53 (2.4) 70 (2) 68 (1.7) .65 <.0001 .36
Duration of disease (y) 24 (18.2-31.38) 15 (8.84-24.19) 4 (2.57-6.68) 5 (3.71-7.04) .07 .001 .48
BMI (kg/m2) 30.1 (1) 31.0 (1.3) 25.5 (1) 25.1 (0.7) .61 .004 .72
Exacerbation number of steroids 3 (0.3) 3 (0.4) 4 (0.59) 4.59 (0.41) .96 .26 .33
Maintenance prednisolone
dose use, n (%)
34 (61.8) 16 (57.1) 3 (15.8) 5 (12.8) .68 .006 .38
Daily prednisolone dose (mg)§ 10 (10-15) 8.75 (5-10) 5 (4-5) 5 (5-5) .044 .13 .3
Daily inhaled corticosteroid
dose (mg/d)jj
2000 (1000-2000) 1400 (1000-2000) 1000 (400-2000) 2000 (800-2000) .056 .31 .25
Pre-FEV1 (L) 2.21 (0.1) 2.06 (0.2) 1.27 (0.1) 1.27 (0.1) .4 .001 .97
Pre-FEV1/FVC ratio (%) 69.6 (1.9) 63.8 (2.7) 50.6 (3.4) 48.6 (2.4) .08 .004 .63
Pre-FEV1 predicted (%) 77.8 (2.8) 69.1 (4.5) 45.6 (4.9) 45.5 (3) .087 .001 .97
Post-FEV1 (L) 2.38 (0.1) 2.25 (0.16) 1.29 (0.14) 1.33 (0.09) .5 <.001 .8
Post-FEV1 predicted (%) 82.9 (2.8) 74.7 (4.7) 47.1 (4.8) 47.4 (2.9) .11 <.0001 .96
Sputum neutrophil count (%) 59.4 (3.2) 70.1 (4.4) 87.6 (2.4) 58.7 (3.3) .052 .003 <.0001
Sputum eosinophil count (%) 3.9 (2.4-6.5) 0.7 (0.4-1.1) 0.6 (0.4-1.0) 2.3 (1.4-3.6) <.0001 .89 .001
Sputum macrophage count (%) 15.9 (11.9-21.3) 17.5 (12.3-24.9) 7.2 (5.1-10.1) 25.6 (20.9-31.2) .7 .001 <.0001
TCC (3106 cells/g sputum) 1.28 (0.92-1.8) 2.62 (1.8-3.8) 10.4 (7.0-15.2) 1.8 (1.3-2.6) .01 <.0001 <.0001
Blood eosinophil 3 109/L 0.23 (0.17-0.31) 0.27 (0.2-0.38) 0.23 (0.17-0.31) 0.22 (0.17-0.28) .51 .45 .9
Blood neutrophil 3 109/L 5.78 (0.3) 5.58 (0.4) 6.17 (0.6) 5.55 (0.4) .68 .39 .35
CFU >107/mL or positive
culture, n (%)
7 (12.7) 9 (32.1) 17 (89.5) 9 (23.1) .034 <.0001 <.0001
VAS score-cough (mm) 30 (3.1) 42 (5.2) 57 (5.9) 37 (4.6) .046 .061 .011
VAS score-dyspnea (mm) 31 (3.5) 39 (4.2) 56 (4.3) 44 (4.6) .13 .011 .11
IL-1b (pg/mL) 40.6 (31.4-52.5) 228.6 (148.7-351.5) 800.9 (444.8-1442) 23.9 (17.2-33.3) <.0001 .001 <.0001
IL-4 (pg/mL) 0.36 (0.36-0.59) 0.36 (0.36-0.59) 0.36 (0.36-0.36) 0.36 (0.36-0.36) .89 .41 .5
Detectable IL-4, n (%) 18 (32.7) 10 (35.7) 3 (15.8) 2 (5.1) .79 .19 .32
IL-5 (pg/mL) 2.7 (1.7-4.5) 2.9 (1.6-5.4) 1.4 (0.7-2.7) 1.5 (0.9-2.3) .88 .12 .87
IL-6 (pg/mL) 20.8 (14.4-29.9) 165.4 (113.4-241.3) 563.1 (342.6-925.5) 524.3 (351.3-782.5) <.0001 <.0001 .84
IL-6R (pg/mL) 174.4 (134.6-226.0) 469.4 (338.4-651.2) 385.2 (283.8-522.9) 108.2 (84.8-138.1) <.0001 .41 <.0001
IL-8 (pg/mL) 1727 (1242-2401) 10,225 (7,320-14,283) 11,934 (9,260-15,379) 3116 (2217-4379) <.0001 .51 <.0001
IL-10 (pg/mL) 0.34 (0.25-0.47) 3.4 (1.9-6.1) 11.5 (6.4-20.6) 0.3 (0.2-0.6) <.0001 .008 <.0001
IL-13 (pg/mL) 10.4 (7.6-14.2) 5.3 (3.9-7.2) 4.2 (2.8-6.4) 3.6 (2.4-5.3) .009 .38 .61
IL-17 (pg/mL) 2.12 (2.12-4.27) 3.44 (2.12-10.2) 2.12 (2.12-2.12) 2.12 (2.12-2.12) .033 .002 .52
Detectable IL-17, n (%) 20 (36.4) 17 (60.7) 2 (10.5) 0 (0.0) .035 .001 .1
CCL-2 (pg/mL) 202 (161.3-252.9) 499.9 (327.7-762.8) 488.9 (377.3-633.4) 744.61 (519.0-1068.3) <.0001 .94 .14
CCL-3 (pg/mL) 19.3 (14.0-26.5) 80.3 (52.8-122.0) 129.5 (84.2-199.3) 51.2 (38.4-68.3) <.0001 .14 .001
CCL-4 (pg/mL) 228.2 (138.3-376.8) 885.5 (586.6-1336.7) 1648.0 (1157.7-2346.1) 846.7 (641.1-1118.3) .001 .041 .007
CCL-5 (pg/mL) 5.8 (4.6-7.2) 20.9 (14.3-30.8) 9.0 (6.1-13.4) 2.2 (1.7-2.8) <.0001 .006 <.0001
CCL-13 (pg/mL) 18.2 (12.7-26.1) 21.4 (14.6-31.4) 15.7 (8.7-28.2) 45.4 (34.1-60.4) .58 .37 .001
CCL-17 (pg/mL) 27.3 (19.2-39.0) 26.1 (15.7-43.2) 14.4 (8.2-25.2) 33.6 (23.5-47.9) .88 .14 .012
CCL-26 (pg/mL) 12.8 (7.9-20.8) 7.1 (4.2-12.1) 3.0 (1.7-5.3) 3.2 (2.0-5.0) .15 .037 .89
CXCL-10 (pg/mL) 428.2 (288.6-635.3) 2002.4 (1359.3-2949.7) 247.6 (118.1-518.7) 362.5 (246.5-533.0) <.0001 <.0001 .33
CXCL-11 (pg/mL) 35.3 (23.2-53.6) 149.9 (81.2-276.9) 6.6 (2.0-22.1) 18.3 (11.5-29.2) <.0001 <.0001 .067
TNF-a (pg/mL) 1.4 (1.1-1.9) 16.0 (10.1-25.3) 75.1 (40.1-140.5) 1.6 (1.0-2.5) <.0001 <.0001 <.0001
VEGF (pg/mL) 1056 (885-1262) 2523 (2011-3166) 1796 (1486-2169) 1209 (1011-1447) <.0001 .041 .01
IFN-g (pg/mL) 0.13 (0.13-0.13) 0.18 (0.13-1.37) 0.39 (0.13-2.05) 0.13 (0.13-0.16) .003 .91 .044
Detectable IFN-g, n (%) 9 (16.4) 14 (50) 10 (52.6) 11 (28.2) .001 .99 .07
Data presented as geometric mean (95% CI) unless stated.
BMI, Body mass index; FVC, forced vital capacity; TCC, total sputum cell count; VAS, visual analog scale; VEGF, vascular endothelial growth factor.
*Pack-year history of current and ex-smokers.
Mean (SEM).
Median (first and third quartiles).
§Dose for only those subjects prescribed daily prednisolone.
jjBeclomethasonedipropionate equivalent.
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TABLE E3. Coefficients (bs) and class proportion in each
cluster in the test study used to predict class membership in
the validation study
Variables Cluster 1 (b1k) Cluster 2 (b2k) Cluster 3 (b3k)
IL-1B 1.63 2.17 0.96
IL-5 26.31 26.50 26.79
IL-6 22.62 21.17 0.14
IL-6R 6.28 5.58 4.72
IL-8 6.64 7.59 7.31
CCL-2 5.56 5.66 6.98
CCL-4 3.59 3.83 4.66
CCL-5 21.36 20.80 22.83
CCL-13 20.04 20.49 20.21
CCL-17 2.13 1.09 1.09
CXCL-11 0.48 0.51 0.29
TNF-a 25.77 25.28 26.57
Constant 263.39 275.75 279.11
Prior probability 0.33 0.33 0.33
Unit of all cytokines is pg/mL; prior probability is equal for each cluster in the test
study.
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TABLE E4. Summary statistics by disease and biological subgroups in the validation study that were identified using linear discriminant analysis
Variable
G1 (asthma in
group 1) (n 5 94)
G2 (asthma in
group 2) (n 5 55)
G3 (asthma in
group 3) (n 5 7)
G4 (COPD in
group 1) (n 5 12)
G5 (COPD in
group 2) (n 5 18)
G6 (COPD in
group 3) (n 5 28)
Males, n (%) 59 (62.8) 27 (49.1) 3 (42.9) 6 (50) 13 (72.2) 22 (78.6)
Current or ex-smokers 25 (26.6) 24 (43.6) 5 (71.4) 12 (100) 18 (100) 28 (100)
Pack-year history* 7.5 (4.6-12.2) 7.3 (3.7-14.5) 20.2 (15.77-26) 39.4 (26.0-59.7) 38.1 (27.6-52.7) 43.6 (34.0-55.8)
Age (y) 51 (1.3) 51 (2.1) 52 (5) 66 (3.2) 70.9 (2.2) 69 (1.7)
Duration of disease (y) 18 (15.2-21.7) 20 (15.4-25.4) 23 (15.8-34.2) 4.1 (2.7-6.3) 3 (2.4-4.8) 4 (3.0-5.6)
BMI (kg/m2) 30.5 (0.7) 29.5 (0.9) 27.2 (2.2) 27.7 (3) 27.5 (1.1) 27.0 (1.0)
Exacerbation number of steroids 3 (0.3) 3 (0.4) 4 (0.8) 2 (0.4) 3 (0.5) 3 (0.6)
Maintenance prednisolone dose use, n (%) 54 (57.4) 28 (50.9) 4 (57.1) 0 (0) 2 (11.1) 3 (10.7)
Daily prednisolone dose (mg)§ 10 (10-15) 10 (6.25-15) 7.5 (5-12.5) 0 (0-0) 7.5 (5-10) 5 (5-7.5)
Daily inhaled corticosteroid dose (mg/d)jj 1600 (1000-2000) 1600 (1000-2000) 1600 (1000-2000) 2000 (1200-2000) 650 (0-2000) 800 (0-1800)
Pre-FEV1/FVC ratio (%) 70.2 (1.2) 65.6 (2.1) 65.2 (2.3) 52.7 (5.9) 50.4 (2.8) 55.3 (2.0)
Pre-FEV1 predicted (%) 70.0 (2.3) 69.5 (3.1) 73.1 (7.6) 47.5 (5.9) 50.3 (5.6) 63.5 (3.5)
Sputum neutrophil count (%) 58.1 (3) 69.8 (3) 56.7 (10.4) 66 (7.4) 79.7 (3.6) 58.7 (4.4)
Sputum eosinophil count (%) 6.5 (4.92-8.58) 3.47 (2.64-4.56) 5.52 (3.68-8.27) 5.23 (2.27-12.05) 2.0 (1.53-2.62) 2.9 (1.97-4.21)
TCC (3 106 cells/g sputum) 1.06 (0.82-1.38) 2.96 (2.01-4.38) 1.46 (0.58-3.67) 2.78 (1.56-4.96) 5.6 (2.99-10.51) 3.4 (2.32-5.0)
IL-1B (pg/mL) 53.7 (41.7-69.1) 425.4 (293.3-617.1) 13.5 (2.8-65.8) 57.7 (29.4-113.5) 1010.6 (501-2038.7) 56.4 (36.9-86.3)
IL-5 (pg/mL) 1.3 (1.05-1.7) 1.4 (1.0-2.0) 0.7 (0.5-1.0) 2.3 (1.0-5.3) 0.7 (0.2-1.9) 0.9 (0.5-1.7)
IL-6 (pg/mL) 25.9 (19.5-34.4) 247.4 (193.2-316.9) 205.9 (105.0-403.6) 27.8 (10.7-72.5) 370.2 (177.0-774.0) 391.4 (255.8-598.9)
IL-6R (pg/mL) 197.7 (140.4-278.5) 818.7 (694.1-965.7) 20.6 (1.6-265.7) 115.1 (53.3-248.7) 216.5 (136.3-343.8) 131.1 (98.6-174.4)
IL-8 (pg/mL) 1241 (816-1886) 14,749 (12,142-17,916) 128.9 (5.1-3228.9) 995.2 (359.5-2755.4) 4122.4 (3552.4-4783.7) 2511.4 (1827.5-3451.3)
IL-10 (pg/mL) 2.4 (1.9-2.9) 3.2 (2.2-4.5) 1.7 (1.1-2.7) 0.3 (0.2-0.5) 7.1 (3.3-15.1) 0.4 (0.2-0.7)
CCL-2 (pg/mL) 178.7 (150.8-211.8) 415.4 (321.9-536.1) 415.3 (207.5-831.1) 335.7 (171.5-657.1) 458.5 (273.9-767.6) 769.3 (530.5-1115.6)
CCL-4 (pg/mL) 110.2 (72.9-166.7) 640.5 (499.4-821.4) 24.9 (4.4-142.0) 226.3 (57.8-885.4) 1999.4 (1031.1-3876.8) 1065.2 (669.9-1693.6)
CCL-5 (pg/mL) 4.5 (3.6-5.6) 19.9 (15.6-25.4) 2.4 (0.8-6.9) 4.4 (2.2-8.8) 10.0 (5.8-17.2) 4.2 (2.9-6.2)
CCL-13 (pg/mL) 16.3 (13.7-19.4) 19.2 (14.3-26.0) 10.3 (5.5-19.1) 29.9 (12.0-74.4) 16.1 (9.4-27.4) 56.2 (40.3-78.5)
CCL-17 (pg/mL) 20.7 (15.8-27.1) 30.2 (22.4-40.7) 8.8 (5.3-14.8) 26.4 (9.6-72.5) 14.4 (7.5-27.5) 51.1 (32.8-79.6)
CXCL-10 (pg/mL) 243.6 (168.7-351.7) 1303.4 (898.0-1892.0) 51.2 (5.9-445.3) 183 (72.4-462.1) 221.0 (90.1-542.0) 379.3 (249.6-576.5)
CXCL-11 (pg/mL) 13.4 (9.4-18.7) 57.3 (36.1-90.7) 16.7 (5.3-52.6) 7.0 (1.4-36.0) 8.9 (2.6-30.1) 25.7 (16.4-40.4)
TNF-a (pg/mL) 1.5 (1.2-1.8) 16.7 (11.0-25.6) 1.9 (0.9-4.2) 0.8 (0.4-1.5) 63.9 (37.4-109.1) 1.8 (1.0-3.2)
Variable
Pairwise comparison between asthma
across the 3 clusters, P value
Pairwise comparison between asthma and
COPD overlap in each cluster, P value
Pairwise comparison between COPD across
the 3 clusters
G1 vs G2 G1 vs G3 G2 vs G3 G1 vs G4 G2 vs G5 G3 vs G6 G4 vs G5 G4 vs G6 G5 vs G6
Males, n (%) .1 .42 .99 .53 .074 .15 .27 .13 .73
Current or ex-smokers .05 .023 .24 <.0001 <.0001 .035 .99 .99 .99
Pack-year history* .97 .16 .2 <.0001 <.0001 .032 .9 .68 .52
Age (y) .95 .83 .83 <.0001 <.0001 <.0001 .17 .32 .56
Duration of disease (y) .57 .48 .66 <.0001 <.0001 <.0001 .54 .97 .43
BMI (kg/m2) .37 .21 .41 .2 .26 .93 .94 .77 .75
Exacerbation number of steroids .8 .45 .37 .26 .89 .27 .38 .57 .7
Maintenance prednisolone dose use, n (%) .44 .99 .99 <.0001 .005 .018 .5 .54 .99
Daily prednisolone dose (mg)§ .67 .29 .46 — .41 .43 — — .56
Daily inhaled corticosteroid dose (mg/d)jj .93 .45 .42 .58 .023 .1 .12 .02 .75
Pre-FEV1/FVC ratio (%) .042 .32 .94 <.0001 <.0001 .025 .64 .58 .15
Pre-FEV1 predicted (%) .9 .72 .69 .001 .003 .23 .72 .033 .042
(Continued)
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TABLE E4. (Continued)
Variable
Pairwise comparison between asthma
across the 3 clusters, P value
Pairwise comparison between asthma and
COPD overlap in each cluster, P value
Pairwise comparison between COPD across
the 3 clusters
G1 vs G2 G1 vs G3 G2 vs G3 G1 vs G4 G2 vs G5 G3 vs G6 G4 vs G5 G4 vs G6 G5 vs G6
Sputum neutrophil count (%) .01 .91 .21 .35 .077 .86 .094 .33 .001
Sputum eosinophil count (%) .003 .76 .31 .59 .033 .18 .015 .098 .18
TCC (3 106 cells/g sputum) <.0001 .6 0.29 .012 .11 .098 .1 .6 .17
IL-1B (pg/mL) <.0001 .01 <.0001 .85 .03 .02 <.0001 .96 <.0001
IL-5 (pg/mL) .7 .19 .15 .14 .078 .68 .078 .16 .59
IL-6 (pg/mL) <.0001 <.0001 .63 .87 .19 .18 <.0001 <.0001 .89
IL-6R (pg/mL) <.0001 <.0001 <.0001 .29 <.0001 .011 .091 .7 .062
IL-8 (pg/mL) <.0001 .003 <.0001 .72 <.0001 .001 <.0001 .011 .024
IL-10 (pg/mL) .12 .45 .23 <.0001 .038 .024 <.0001 .83 <.0001
CCL-2 (pg/mL) <.0001 .017 .99 .022 .72 .15 .44 .03 .11
CCL-4 (pg/mL) <.0001 .032 <.0001 .26 <.0001 <.0001 .001 .007 .12
CCL-5 (pg/mL) <.0001 .12 <.0001 .94 .013 .23 .055 .92 .012
CCL-13 (pg/mL) .31 .23 .16 .043 .56 <.0001 .15 .12 <.0001
CCL-17 (pg/mL) .074 .082 .007 .57 .026 .001 .25 .18 .002
CXCL-10 (pg/mL) <.0001 .024 <.0001 .6 <.0001 .006 .74 .17 .24
CXCL-11 (pg/mL) <.0001 .73 .08 .26 .001 .43 .77 .084 .071
TNF-a (pg/mL) <.0001 .59 .001 .042 .002 .9 <.0001 .12 <.0001
Groups 1, 2 and 3 were predicted using linear discriminant analysis. Data presented as geometric mean (95% CI) unless otherwise stated.
BMI, Body mass index; FVC, forced vital capacity; TCC, total sputum cell count.
*Pack-year history of current and ex-smokers.
Mean (SEM).
Median (first and third quartiles).
§Dose for only those subjects prescribed daily prednisolone.
jjBeclomethasonedipropionate equivalent.
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TABLE E5. Summary statistics by disease and biological subgroups in the validation data set that were obtained using IL1b cutoff
and disease status
Variable
Group 1 Group 2 Group 3
Pairwise comparison,
P value
G1 (asthma in
group 1) (n 5 103)
G2 (asthma in
group 2) (n 5 63)
G3 (COPD in
group 2) (n 5 26)
G4 (COPD in
group 3) (n 5 32)
G1 vs
G2
G2 vs
G3
G3 vs
G4
Males, n (%) 66 (64.1) 32 (50.8) 19 (73.1) 22 (68.7) .09 .05 .72
Current or ex-smokers 28 (27.2) 28 (44.4) 26 (100) 32 (100) .022 <.0001 .99
Pack-year history* 9.5 (5.8-15.7) 6.9 (4.0-12.0) 40.4 (30.2-54.1) 41.5 (33.5-51.6) .4 <.0001 .88
Age (y) 49 (1.2) 52 (2.0) 71 (2.0) 68 (1.6) .29 <.0001 .18
Duration of disease (y) 17 (14.1-20.7) 21 (17.3-25.7) 4.2 (3.1-5.7) 3.6 (2.7-4.7) .15 <.0001 .45
BMI (kg/m2) 29.9 (0.7) 29.5 (0.8) 27.7 (0.9) 27.0 (1.3) .71 .2 .67
Exacerbation number of steroids 3.5 (0.3) 3.1 (0.4) 3.3 (0.6) 2.3 (0.4) .39 .7 .12
Maintenance prednisolone dose
use, n (%)
57 (55.3) 32 (50.8) 3 (11.5) 2 (6.2) .57 .001 .65
Daily prednisolone dose (mg)§ 10 (8-15) 10 (5-12.5) 5 (5-10) 6.25 (5-7.5) .27 .22 .99
Daily inhaled corticosteroid
dose (mg/d)jj
1600 (1000-2000) 2000 (1600-2000) 1000 (0-2000) 900 (200-2000) .07 .028 .68
Pre-FEV1/FVC ratio (%) 70.1 (1.2) 66.3 (1.9) 49.1 (2.4) 56.6 (2.4) .069 <.0001 .033
Pre-FEV1 predicted (%) 71.2 (2.3) 69.6 (2.7) 51.0 (4.4) 60.2 (3.6) .66 <.0001 .11
Sputum neutrophil count (%) 59.0 (2.8) 67.9 (3.2) 75.9 (3.8) 59.2 (4.2) .04 .15 .005
Sputum eosinophil count (%) 5.6 (4.3-7.3) 4.4 (3.4-5.8) 2.1 (1.6-2.7) 3.9 (2.5-5.9) .24 .001 .024
TCC (3 106 cells/g sputum) 0.98 (0.74-1.28) 2.5 (1.8-3.7) 4.8 (3.0-7.8) 3.1 (2.2-4.5) <.0001 .053 .15
IL-1B (pg/mL) 37.0 (29.1-47.0) 485.8 (364.8-646.8) 642.5 (370.5-1114.2) 40.0 (28.2-56.6) <.0001 .34 <.0001
IL-5 (pg/mL) 1.2 (1.0-1.5) 1.5 (1.1-2.1) 1.0 (0.4-2.4) 1.0 (0.6-1.7) .33 .33 .94
IL-6 (pg/mL) 34.7 (25.6-47.0) 149.5 (107.4-207.9) 340.3 (169.5-683.0) 157.7 (88.7-280.2) <.0001 .02 .098
IL-6R (pg/mL) 153.2 (102.7-228.6) 774.7 (659.6-910.0) 239 (168.2-339.5) 101.7 (74.1-139.5) <.0001 <.0001 .001
IL-8 (pg/mL) 975.0 (596.9-1592.3) 11958 (9587-14917) 3883 (3164.0-4765.4) 1646.2 (1040.9-2603.3) <.0001 <.0001 .003
IL-10 (pg/mL) 2.2 (1.8-2.6) 3.2 (2.4-4.4) 2.8 (1.2-6.7) 0.4 (0.2-0.6) .026 .72 <.0001
CCL-2 (pg/mL) 202.1 (166.8-244.9) 346.5 (279.5-429.6) 641.5 (405.6-1014.8) 488.3 (340.0-701.4) <.0001 .008 .36
CCL-4 (pg/mL) 101.3 (65.3-157.3) 491.6 (368.5-655.9) 1533.6 (710.3-3311.1) 631.5 (382.8-1041.7) <.0001 .001 .055
CCL-5 (pg/mL) 5.2 (4.1-6.7) 12.9 (9.6-17.3) 9.1 (6.1-13.7) 3.7 (2.54-5.5) <.0001 .21 .003
CCL-13 (pg/mL) 14.7 (12.4-17.5) 20.1 (15.4-26.2) 27.3 (15.5-48.3) 39.4 (27.4-56.6) .046 .28 .28
CCL-17 (pg/mL) 19.5 (15.1-25.0) 26.9 (19.9-36.3) 24.4 (12.7-46.9) 35.7 (22.9-55.6) .11 .76 .33
CXCL-10 (pg/mL) 250.4 (163.4-383.8) 850.2 (592.4-1220.2) 251.1 (123.0-512.7) 297.7 (194.2-456.6) <.0001 .001 .68
CXCL-11 (pg/mL) 17.3 (12.4-24.2) 33.5 (21.1-53.2) 12.3 (4.9-30.8) 15.8 (7.8-31.8) .022 .037 .67
TNF-a (pg/mL) 1.6 (1.3-2.0) 11.9 (7.7-18.5) 22.6 (10.2-50.0) 1.2 (0.7-2.1) <.0001 .15 <.0001
Data presented as geometric mean (95% CI) unless otherwise stated.
BMI, Body mass index; group 1, pure asthma (IL-1B < 130 pg/mL); group 2, asthma and COPD overlap (IL-1B >_ 130 pg/mL); group 3, pure COPD (IL-1B < 130 pg/mL); FVC,
forced vital capacity; TCC, total sputum cell count.
*Pack-year history of current and ex-smokers.
Mean (SEM).
Median (first and third quartiles).
§Dose for only those subjects prescribed daily prednisolone.
jjBeclomethasonedipropionate equivalent.
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